Results 281 to 290 of about 380,707 (403)

Myosin VI controls localization of golgi satellites at active presynaptic boutons. [PDF]

Cell Mol Life Sci
Hertrich N, Han Y, Doil N, Ranti D, Eickholt B, Konietzny A, Mikhaylova M.   +6 more
europepmc   +1 more source

A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance.

Developmental Cell, 2009
E. van Rooij, Daniel Quiat, Brett A. Johnson, L. Sutherland, X. Qi, J. Richardson, R. Kelm, E. Olson   +7 more
semanticscholar   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Cardiac Myosin-Binding Protein C (cMyC) as a Novel Biomarker for Early Diagnosis of Myocardial Infarction: A Brief Review. [PDF]

Cureus
Akyuz B.
europepmc   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Non-muscle myosin II is a promising therapeutic target. [PDF]

Trends Pharmacol Sci
Miller CA, Quinones-Hinojosa A, Rosenfeld SS.   +2 more
europepmc   +1 more source

Study of the Function and Dynamics of Myosin II and Actin in Cytokinesis: A Dissertation

, 2009
Mian Zhou
openalex   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Rapid screening for acute rheumatic fever using machine learning analysis of host tissue reactive antibodies. [PDF]

Sci Rep
Vo B, Rafeek RAM, Surve NZ, Karmarkar MG, Reeves B, Rishi G, Pandey M, Good MF, Ketheesan N.   +8 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source